News headlines about ImmunoGen (NASDAQ:IMGN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.2565501768137 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of analysts have commented on IMGN shares. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Tuesday, October 31st. Jefferies Group reiterated a “buy” rating and set a $9.00 target price on shares of ImmunoGen in a research report on Thursday, October 12th. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 target price on shares of ImmunoGen in a research report on Friday, November 3rd. Finally, BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $7.83.
ImmunoGen (NASDAQ:IMGN) opened at $8.03 on Friday. ImmunoGen has a 1-year low of $2.20 and a 1-year high of $8.84. The firm has a market capitalization of $1,061.97, a price-to-earnings ratio of -6.18 and a beta of 2.20. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3148898/immunogen-imgn-getting-somewhat-positive-media-coverage-study-finds.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.